{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:49:35Z","timestamp":1782377375674,"version":"3.54.5"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T00:00:00Z","timestamp":1582848000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T00:00:00Z","timestamp":1582848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s40266-020-00756-z","type":"journal-article","created":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T03:03:48Z","timestamp":1582859028000},"page":"263-270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Benzodiazepine Prescribing in People with Chronic Obstructive Pulmonary Disease: Clinical Considerations"],"prefix":"10.1007","volume":"37","author":[{"given":"David C.","family":"Currow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera R.","family":"Agar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,28]]},"reference":[{"issue":"2","key":"756_CR1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/MCP.0000000000000351","volume":"23","author":"SC Tsai","year":"2017","unstructured":"Tsai SC. Chronic obstructive pulmonary disease and sleep related disorders. Curr Opin Pulm Med. 2017;23(2):124\u20138.","journal-title":"Curr Opin Pulm Med."},{"key":"756_CR2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02277-2016","author":"MJ Johnson","year":"2017","unstructured":"Johnson MJ, Yorke J, Hansen-Flaschen J, Lansing R, Ekstr\u00f6m M, Similowski T, et al. Towards an expert consensus to delineate a clinical syndrome of chronic breathlessness. Eur Respir J. 2017. https:\/\/doi.org\/10.1183\/13993003.02277-2016.","journal-title":"Eur Respir J."},{"key":"756_CR3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00164-2019","author":"D Singh","year":"2019","unstructured":"Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J. 2019. https:\/\/doi.org\/10.1183\/13993003.00164-2019.","journal-title":"Eur Respir J."},{"issue":"4","key":"756_CR4","first-page":"1205","volume":"127","author":"ME Kunik","year":"2005","unstructured":"Kunik ME, Roundy K, Veazey C, Souchek J, Richardson P, Wray NP, et al. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest. 2005;127(4):1205\u201311.","journal-title":"Chest"},{"issue":"4 Suppl","key":"756_CR5","doi-asserted-by":"publisher","first-page":"43S","DOI":"10.1378\/chest.08-0342","volume":"134","author":"J Maurer","year":"2008","unstructured":"Maurer J, Rebbapragada V, Borson S, Goldstein R, Kunik ME, Yohannes AM, et al. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest. 2008;134(4 Suppl):43S\u201356S.","journal-title":"Chest"},{"issue":"2","key":"756_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jpainsymman.2019.09.021","volume":"59","author":"DC Currow","year":"2020","unstructured":"Currow DC, Chang S, Reddel H, Kochovska S, Ferreira D, Johnson MJ, et al. Breathlessness, anxiety, depression and function\u2014the BAD-F study: a cross-sectional, population prevalence study in adults. J Pain Symptom Manag. 2020;59(2):197\u2013205.e2.","journal-title":"J Pain Symptom Manag"},{"issue":"5","key":"756_CR7","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1378\/chest.121.5.1434","volume":"121","author":"K Nishimura","year":"2002","unstructured":"Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002;121(5):1434\u201340.","journal-title":"Chest"},{"issue":"9","key":"756_CR8","doi-asserted-by":"publisher","first-page":"538","DOI":"10.4140\/TCP.n.2013.538","volume":"28","author":"JY Wick","year":"2013","unstructured":"Wick JY. The history of benzodiazepines. Consult Pharm. 2013;28(9):538\u201348.","journal-title":"Consult Pharm"},{"key":"756_CR9","first-page":"2121","volume":"61","author":"LP Longo","year":"2000","unstructured":"Longo LP, Johnson B. Addiction: part 1. Benzodiazepines\u2014side effects, abuse risk and alternatives. Am Fam Physician. 2000;61:2121\u20138.","journal-title":"Am Fam Physician."},{"issue":"1","key":"756_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11920-015-0642-5","volume":"18","author":"M Lader","year":"2016","unstructured":"Lader M, Kyriacou A. Withdrawing benzodiazepines in patients with anxiety disorders. Curr Psychiatry Rep. 2016;18(1):8.","journal-title":"Curr Psychiatry Rep."},{"issue":"1","key":"756_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1467-842X.2000.tb00715.x","volume":"24","author":"AF Jorm","year":"2000","unstructured":"Jorm AF, Grayson D, Creasey H, Waite L, Broe GA. Long-term benzodiazepine use by elderly people living in the community. Aust N Z J Public Health. 2000;24(1):7\u201310.","journal-title":"Aust N Z J Public Health"},{"issue":"5","key":"756_CR12","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.genhosppsych.2006.05.008","volume":"28","author":"GE Simon","year":"2006","unstructured":"Simon GE, Ludman EJ. Outcome of new benzodiazepine prescriptions to older adults in primary care. Gen Hosp Psychiatry. 2006;28(5):374\u20138.","journal-title":"Gen Hosp Psychiatry"},{"issue":"1","key":"756_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2165\/00003088-199835010-00004","volume":"35","author":"A H\u00e4mmeralein","year":"1998","unstructured":"H\u00e4mmeralein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharmacodynamics changes in the elderly. Clin Pharmacokinet. 1998;35(1):49\u201364.","journal-title":"Clin Pharmacokinet"},{"key":"756_CR14","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/thx.31.5.548","volume":"31","author":"DM Geddes","year":"1976","unstructured":"Geddes DM, Rudolf M, Saunders KB. Effect of nitrazepam and flurazepam on the ventilator response to carbon dioxide. Thorax. 1976;31:548\u201351.","journal-title":"Thorax"},{"key":"756_CR15","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2147\/COPD.S98082","volume":"11","author":"K-M Lu","year":"2016","unstructured":"Lu K-M, Zhu J-PZX-M. The effect of benzodiazepines on insomnia in patients with chronic obstructive pulmonary disease: a meta-analysis of treatment efficacy and safety. Int J COPD. 2016;11:675\u201385.","journal-title":"Int J COPD"},{"issue":"Suppl 3A","key":"756_CR16","doi-asserted-by":"publisher","first-page":"25S","DOI":"10.1016\/0002-9343(90)90282-I","volume":"88","author":"C Guilleminault","year":"1990","unstructured":"Guilleminault C. Benzodiazepines, breathing and sleep. Am J Med. 1990;88(Suppl 3A):25S\u20138S.","journal-title":"Am J Med"},{"issue":"1","key":"756_CR17","first-page":"24","volume":"19","author":"W Sieghart","year":"1994","unstructured":"Sieghart W. Pharmacology of benzodiazepine receptors: an update. J Psychiatr Neurosci. 1994;19(1):24\u20139.","journal-title":"J Psychiatr Neurosci."},{"issue":"2","key":"756_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1136\/thoraxjnl-2012-202374","volume":"68","author":"E Obiora","year":"2013","unstructured":"Obiora E, Hubbard R, Sanders RD, Myles PR. The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort. Thorax. 2013;68(2):163\u201370.","journal-title":"Thorax"},{"issue":"1","key":"756_CR19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/gbb.12321","volume":"16","author":"DN Stephens","year":"2017","unstructured":"Stephens DN, King SL, Lambert JJ, Belelli D, Duka T. GABAA receptor subtype involvement in addictive behaviour. Genes Brain Behav. 2017;16(1):149\u201384.","journal-title":"Genes Brain Behav."},{"key":"756_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jpsychires.2019.08.014","volume":"118","author":"TR Chen","year":"2019","unstructured":"Chen TR, Huang HC, Hsu JH, Ouyang WC, Lin KC. Pharmacological and psychological interventions for generalized anxiety disorder in adults: a network meta-analysis. J Psychiatr Res. 2019;118:73\u201383. https:\/\/doi.org\/10.1016\/j.jpsychires.2019.08.014.","journal-title":"J Psychiatr Res"},{"issue":"5","key":"756_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/YIC.0000000000000276","volume":"34","author":"M Shinfuku","year":"2019","unstructured":"Shinfuku M, Kishimoto T, Uchida H, Suzuki T, Mimura M, Kikuchi T. Effectiveness and safety of long-term benzodiazepine use in anxiety disorders: a systematic review and meta-analysis. Int Clin Psychopharmacol. 2019;34(5):211\u201321.","journal-title":"Int Clin Psychopharmacol"},{"issue":"10173","key":"756_CR22","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S0140-6736(18)31793-8","volume":"393","author":"A Slee","year":"2019","unstructured":"Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019;393(10173):768\u201377.","journal-title":"Lancet"},{"issue":"8","key":"756_CR23","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/14656566.2018.1472767","volume":"19","author":"AF Gomez","year":"2018","unstructured":"Gomez AF, Barthel AL, Hofmann SG. Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review. Expert Opin Pharmacother. 2018;19(8):883\u201394.","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"756_CR24","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/S2215-0366(14)70329-3","volume":"1","author":"E Mayo-Wilson","year":"2014","unstructured":"Mayo-Wilson E, Dias S, Mavranezouli I, Kew K, Clark DM, Ades AE, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2014;1(5):368\u201376. https:\/\/doi.org\/10.1016\/S2215-0366(14)70329-3.","journal-title":"Lancet Psychiatry."},{"key":"756_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd001206.pub3","author":"T Williams","year":"2017","unstructured":"Williams T, Hattingh CJ, Kariuki CM, Tromp SA, van Balkom AJ, Ipser JC, et al. Pharmacotherapy for social anxiety disorder (SAnD). Cochrane Database Syst Rev. 2017. https:\/\/doi.org\/10.1002\/14651858.cd001206.pub3.","journal-title":"Cochrane Database Syst Rev."},{"key":"756_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd011567.pub2","author":"I Bighelli","year":"2016","unstructured":"Bighelli I, Trespidi C, Castellazzi M, Cipriani A, Furukawa TA, Girlanda F, et al. Antidepressants and benzodiazepines for panic disorder in adults. Cochrane Database Syst Rev. 2016. https:\/\/doi.org\/10.1002\/14651858.cd011567.pub2.","journal-title":"Cochrane Database Syst Rev."},{"issue":"3","key":"756_CR27","doi-asserted-by":"publisher","first-page":"360","DOI":"10.5665\/sleep.1698","volume":"35","author":"R Budhiraja","year":"2012","unstructured":"Budhiraja R, Parthasarathy S, Budhiraja P, Habib MP, Wendel C, Quan SF. Insomnia in patients with COPD. Sleep. 2012;35(3):360\u201375.","journal-title":"Sleep"},{"issue":"9","key":"756_CR28","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s40263-014-0198-7","volume":"28","author":"A Winkler","year":"2014","unstructured":"Winkler A, Auer C, Doering BK, Rief W. Drug treatment of primary insomnia: a meta-analysis of polysomnographic randomized controlled trials. CNS Drugs. 2014;28(9):799\u2013816.","journal-title":"CNS Drugs"},{"issue":"9","key":"756_CR29","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s11606-007-0251-z","volume":"22","author":"N Buscemi","year":"2007","unstructured":"Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gener Intern Med. 2007;22(9):1335\u201350.","journal-title":"J Gener Intern Med"},{"key":"756_CR30","first-page":"CD007354","volume":"10","author":"ST Simon","year":"2016","unstructured":"Simon ST, Higginson IJ, Booth S, Harding R, Weing\u00e4rtner V, Bausewein C. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev. 2016;10:CD007354.","journal-title":"Cochrane Database Syst Rev."},{"issue":"3","key":"756_CR31","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00520-015-2903-6","volume":"24","author":"AR Peoples","year":"2016","unstructured":"Peoples AR, Bushunow PW, Garland SN, Heckler CE, Roscoe JA, Peppone LL, et al. Buspirone for management of dyspnea in cancer patients receiving chemotherapy: a randomized placebo-controlled URCC CCOP study. Support Care Cancer. 2016;24(3):1339\u201347.","journal-title":"Support Care Cancer"},{"key":"756_CR32","doi-asserted-by":"crossref","unstructured":"Currow DC, Ekstr\u00f6m M, Louw S, Hill J, Fazekas B, Clark K, et al. Sertraline in symptomatic chronic breathlessness: a double blind, randomised trial. Eur Respir J. 2019;53(1).","DOI":"10.1183\/13993003.01270-2018"},{"issue":"7","key":"756_CR33","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1089\/jpm.2012.0505","volume":"16","author":"P Allcroft","year":"2013","unstructured":"Allcroft P, Margitanovic V, Greene A, Agar MR, Clark K, Abernethy AP, et al. The role of benzodiazepines in breathlessness: a single site, open label pilot of sustained release morphine together with clonazepam. J Palliat Med. 2013;16(7):741\u20134.","journal-title":"J Palliat Med"},{"issue":"2","key":"756_CR34","first-page":"225","volume":"162","author":"AM Holbrook","year":"2000","unstructured":"Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ. 2000;162(2):225\u201333.","journal-title":"CMAJ"},{"issue":"7","key":"756_CR35","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s40261-016-0397-8","volume":"36","author":"Y Murphy","year":"2016","unstructured":"Murphy Y, Wilson E, Goldner EM, Fischer B. Benzodiazepine use, misuse, and harm at the population level in Canada: a comprehensive narrative review of data and developments since 1995. Clin Drug Investig. 2016;36(7):519\u201330.","journal-title":"Clin Drug Investig."},{"key":"756_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2019.11.003","author":"TN Poly","year":"2019","unstructured":"Poly TN, Islam MM, Yang HC, Li YJ. Association between benzodiazepines use and risk of hip fracture in the elderly people: a meta-analysis of observational studies. Jt Bone Spine. 2019. https:\/\/doi.org\/10.1016\/j.jbspin.2019.11.003(Epub 25 Nov 2019).","journal-title":"Jt Bone Spine."},{"issue":"24","key":"756_CR37","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1001\/jama.1997.03550240060035","volume":"278","author":"PD Nowell","year":"1997","unstructured":"Nowell PD, Mazumdar S, Buysse DJ, Dew MA, Reynolds CF 3rd, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA. 1997;278(24):2170\u20137.","journal-title":"JAMA"},{"issue":"6","key":"756_CR38","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/0004867415616695","volume":"50","author":"AK Parsaik","year":"2016","unstructured":"Parsaik AK, Mascarenhas SS, Khosh-Chashm D, Hashmi A, John V, Okusaga O, et al. Mortality associated with anxiolytic and hypnotic drugs: a systematic review and meta-analysis. Aust N Z J Psychiatry. 2016;50(6):520\u201333.","journal-title":"Aust N Z J Psychiatry"},{"issue":"27","key":"756_CR39","doi-asserted-by":"publisher","first-page":"e1110","DOI":"10.1097\/MD.0000000000001110","volume":"94","author":"WS Chung","year":"2015","unstructured":"Chung WS, Lai CY, Lin CL, Kao CH. Adverse respiratory events associated with hypnotics use in patients of chronic obstructive pulmonary disease: a population-based case-control study. Medicine (Baltimore). 2015;94(27):e1110.","journal-title":"Medicine (Baltimore)"},{"key":"756_CR40","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2147\/COPD.S98082","volume":"11","author":"XM Lu","year":"2016","unstructured":"Lu XM, Zhu JP, Zhou XM. The effect of benzodiazepines on insomnia in patients with chronic obstructive pulmonary disease: a meta-analysis of treatment efficacy and safety. Int J Chron Obstruct Pulmon Dis. 2016;11:675\u201385.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"756_CR41","first-page":"CD011090","volume":"7","author":"M Mason","year":"2015","unstructured":"Mason M, Cates CJ, Smith I. Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea. Cochrane Database Syst Rev. 2015;7:CD011090.","journal-title":"Cochrane Database Syst Rev."},{"issue":"2","key":"756_CR42","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1183\/09031936.00071014","volume":"44","author":"R Rodriguez-Roisin","year":"2014","unstructured":"Rodriguez-Roisin R, Garcia-Aymerich J. Should we exercise caution with benzodiazepine use in patients with COPD? Eur Respir J. 2014;44(2):284\u20136.","journal-title":"Eur Respir J"},{"issue":"2","key":"756_CR43","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1183\/09031936.00008014","volume":"44","author":"NT Vozoris","year":"2014","unstructured":"Vozoris NT, Fischer HD, Wang X, Stephenson AL, Gershon AS, Gruneir A, et al. Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J. 2014;44(2):332\u201340.","journal-title":"Eur Respir J"},{"key":"756_CR44","doi-asserted-by":"publisher","first-page":"g445","DOI":"10.1136\/bmj.g445","volume":"348","author":"MP Ekstr\u00f6m","year":"2014","unstructured":"Ekstr\u00f6m MP, Bornefalk-Hermansson A, Abernethy AP, Currow DC. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ. 2014;348:g445.","journal-title":"BMJ"},{"issue":"7","key":"756_CR45","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.5665\/sleep.4808","volume":"38","author":"SJ Chen","year":"2015","unstructured":"Chen SJ, Yeh CM, Chao TF, Liu CJ, Wang KL, Chen TJ, et al. The use of benzodiazepine receptor agonists and risk of respiratory failure in patients with chronic obstructive pulmonary disease: a nationwide population-based case-control study. Sleep. 2015;38(7):1045\u201350.","journal-title":"Sleep"},{"key":"756_CR46","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40266-013-0056-1","volume":"30","author":"NT Vozoris","year":"2013","unstructured":"Vozoris NT, Fischer HD, Wang X, Anderson GM, Bell CM, Gershon AS, et al. Benzodiazepine use among older adults with chronic obstructive pulmonary disease: a population-based cohort study. Drugs Aging. 2013;30:183\u201392.","journal-title":"Drugs Aging"},{"issue":"10","key":"756_CR47","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1046\/j.1532-5415.2001.49262.x","volume":"49","author":"K Tu","year":"2001","unstructured":"Tu K, Mamdani MM, Hux JE, Tu J. Progressive trends in the prevalence of benzodiazepine prescribing in older people in Ontario, Canada. J Am Geriatri Soc. 2001;49(10):1341\u20135.","journal-title":"J Am Geriatri Soc."},{"issue":"6","key":"756_CR48","doi-asserted-by":"publisher","first-page":"466","DOI":"10.5414\/CP202904","volume":"55","author":"T Mell","year":"2017","unstructured":"Mell T, Jacob L, Fuhr I, Dick S, Rapp MA, Kostev K. Patterns of benzodiazepine prescribing by neuropsychiatrists and general practitioners for elderly patients in Germany in 2014. Int J Clin Pharmacol Ther. 2017;55(6):466\u201371.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"756_CR49","unstructured":"NICE National Institute for Health and Care Excellence. Clinical Knowledge Summary - insomnia. https:\/\/www.nice.org.uk\/insomnia. Accessed 24 Feb 2020."},{"issue":"6","key":"756_CR50","first-page":"649","volume":"12","author":"ES Ford","year":"2015","unstructured":"Ford ES, Wheaton AG. Trends in outpatient visits with benzodiazepines among US adults with and without bronchitis or chronic obstructive pulmonary disease from 1999 to 2010. COPD. 2015;12(6):649\u201357.","journal-title":"COPD."},{"issue":"6","key":"756_CR51","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/pds.3951","volume":"25","author":"CN Kaufmann","year":"2016","unstructured":"Kaufmann CN, Spira AP, Alexander GC, Rutkow L, Mojtabai R. Trends in prescribing of sedative-hypnotic medications in the USA: 1993-2010. Pharmacoepidemiol Drug Saf. 2016;25(6):637\u201345.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"756_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/JCP.0000000000000831","volume":"38","author":"DJ Greenblatt","year":"2019","unstructured":"Greenblatt DJ, Harmatz JS, Shader RI. Update on psychotropic drug prescribing in the United States 2014-2015. J Clin Psychopharmacol. 2019;38(1):1\u20133.","journal-title":"J Clin Psychopharmacol"},{"key":"756_CR53","unstructured":"Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2017. http:\/\/goldcopd.org. Accessed 15 Jan 2020."},{"key":"756_CR54","unstructured":"National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16\u00a0s: diagnosis and management. 2010. https:\/\/www.nice.org.uk\/guidance\/cg101\/resources\/chronic-obstructive-pulmonary-disease-in-over-16s-diagnosis-and-management-pdf-35109323931589. Accessed 15 Jan 2020."},{"issue":"4","key":"756_CR55","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1164\/rccm.201111-2042ST","volume":"185","author":"MB Parshall","year":"2012","unstructured":"Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4):435\u201352.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"756_CR56","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2165\/00003495-200363040-00004","volume":"63","author":"CF George","year":"2003","unstructured":"George CF, Bayliff CD. Management of insomnia in patients with chronic obstructive pulmonary disease. Drugs. 2003;63(4):379\u201387.","journal-title":"Drugs."},{"issue":"4","key":"756_CR57","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1093\/sleep\/16.4.318","volume":"16","author":"RD Steens","year":"1993","unstructured":"Steens RD, Pouliot Z, Millar TW, Kryger MH, George CF. Effects of zolpidem and triazolam on sleep and respiration in mild to moderate chronic obstructive pulmonary disease. Sleep. 1993;16(4):318\u201326.","journal-title":"Sleep"},{"issue":"1","key":"756_CR58","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11325-008-0196-4","volume":"13","author":"M Kryger","year":"2009","unstructured":"Kryger M, Roth T, Wang-Weigand S, Zhang J. The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease. Sleep Breath. 2009;13(1):79\u201384.","journal-title":"Sleep Breath"},{"key":"756_CR59","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1590\/S0100-879X2008001000016","volume":"41","author":"DM Nunes","year":"2008","unstructured":"Nunes DM, Mota RM, Machado MO, Pereira ED, Bruin VM, Bruin PF. Effect of melatonin administration on subjective sleep quality in chronic obstructive pulmonary disease. Braz J Med Biol Res. 2008;41:926\u201331.","journal-title":"Braz J Med Biol Res"},{"issue":"2","key":"756_CR60","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1155\/2011\/745047","volume":"18","author":"DD Marciniuk","year":"2011","unstructured":"Marciniuk DD, Goodridge D, Hernandez P, Rocker G, Balter M, Bailey P, et al. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2011;18(2):69\u201378.","journal-title":"Can Respir J"},{"issue":"7","key":"756_CR61","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1513\/AnnalsATS.201501-034OC","volume":"12","author":"M Ekstrom","year":"2015","unstructured":"Ekstrom M, Nilsson F, Abernethy AP, Currow DC. Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease. A systematic review. Ann Am Thoracic Soc. 2015;12(7):1079\u201392.","journal-title":"Ann Am Thoracic Soc"},{"key":"756_CR62","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/thoraxjnl-2016-209868","volume":"73","author":"M Ekstr\u00f6m","year":"2018","unstructured":"Ekstr\u00f6m M, Bajwah S, Bland JM, Currow DC, Hussain J, Johnson MJ. One evidence base; three stories: do opioids relieve chronic breathlessness? Thorax. 2018;73:88\u201390.","journal-title":"Thorax"},{"key":"756_CR63","first-page":"1695","volume":"10","author":"T Halvorsen","year":"2015","unstructured":"Halvorsen T, Martinussen PE. Benzodiazepine us in COPD: empirical evidence from Norway. Int J COPD. 2015;10:1695\u2013702.","journal-title":"Int J COPD"},{"issue":"1","key":"756_CR64","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1360-0443.2008.02364.x","volume":"104","author":"JM Parr","year":"2009","unstructured":"Parr JM, Kavanagh DJ, Cahill L, Mitchell G, McD Young R. Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta-analysis. Addiction. 2009;104(1):13\u201324.","journal-title":"Addiction"},{"key":"756_CR65","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1192\/bjp.189.3.213","volume":"189","author":"RC Voshaar","year":"2006","unstructured":"Voshaar RC, Couv\u00e9e JE, van Balkom AJ, Mulder PG, Zitman FG. Strategies for discontinuing long-term benzodiazepine use: meta-analysis. Br J Psychiatry. 2006;189:213\u201320.","journal-title":"Br J Psychiatry"},{"issue":"2","key":"756_CR66","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1192\/bjp.bp.113.126003","volume":"204","author":"RL Gould","year":"2014","unstructured":"Gould RL, Coulson MC, Patel N, Highton-Williamson E, Howard RJ. Interventions for reducing benzodiazepine use in older people: meta-analysis of randomised controlled trials. Br J Psychiatry. 2014;204(2):98\u2013107.","journal-title":"Br J Psychiatry"},{"issue":"590","key":"756_CR67","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.3399\/bjgp11X593857","volume":"61","author":"K Mugunthan","year":"2011","unstructured":"Mugunthan K, McGuire T, Glasziou P. Minimal interventions to decrease long-term use of benzodiazepines in primary care: a systematic review and meta-analysis. Br J Gen Pract. 2011;61(590):e573\u20138.","journal-title":"Br J Gen Pract"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-020-00756-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-020-00756-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-020-00756-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:58:49Z","timestamp":1614387529000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-020-00756-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,28]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["756"],"URL":"https:\/\/doi.org\/10.1007\/s40266-020-00756-z","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,28]]},"assertion":[{"value":"28 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"David C. Currow has received intellectual property payments and consultancy fees from Mayne Pharma Pty Ltd, consultancy fees from Specialist Therapeutics Pty Ltd, and is on an Advisory Board for Helsinn Pharmaceuticals. Meera R. Agar declares no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"No funding was associated with developing this review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}